A research team led by Run-Run Shaw Hospital, Zhejiang University School of Medicine published a comprehensive review in ExRNA that catalogs the diverse roles of extracellular vesicle-associated RNAs (EV-RNAs) in the development and progression of inflammatory bowel disease (IBD). By integrating the latest findings from multi-omics studies and animal experiments, this review points out that EV-RNA has great potential to serve as a non-invasive biomarker for early detection and disease monitoring of IBD, and also as a target for next-generation targeted therapies. This study provides a solid theoretical basis to advance personalized precision treatment for the millions of IBD patients worldwide who suffer from chronic recurrent gastrointestinal disorders.
IBD is a lifelong, recurrent inflammatory disease that affects the gastrointestinal tract and is a growing global public health concern. This includes two main types. One is Crohn’s disease (CD), which causes transmural inflammation that can affect any part of the gastrointestinal tract, and the other is ulcerative colitis (UC), which is characterized by persistent superficial inflammation confined to the colorectal mucosa. Over the past few decades, its incidence has increased rapidly in both industrialized and newly industrialized countries. By 2045, the prevalence of IBD in early industrialized regions is projected to exceed 1% of the population.
For people with IBD, recurring symptoms such as abdominal pain, diarrhea, and weight loss often interfere with daily life and seriously impact quality of life. Current clinical management still faces long-standing challenges. Diagnosis relies heavily on invasive endoscopy. Traditional anti-inflammatory drugs and biological therapies often cause systemic side effects, and many patients eventually develop drug resistance and lose response to treatment. Therefore, there is an urgent and unmet need for more accurate non-invasive diagnostic tools and safer and more targeted treatment strategies.
Against this background, a research team led by Professor Xiyang Wei of Zhejiang University School of Medicine, Sir Runrun Shaw Hospital, and Zhejiang Key Laboratory of Multi-omic Precise Diagnosis and Treatment of Liver Diseases, in collaboration with researchers from Zhejiang Chinese Medical University, conducted a systematic and detailed summary of the rapidly developing field of EV-RNA research in IBD. This study integrates cutting-edge findings from hundreds of recent studies and comprehensively demonstrates how EV-RNA regulates core processes associated with IBD and its potential clinical applications.
Extracellular vesicles (EVs) are small membrane-bound “biological packages” secreted by almost all cell types. These nanoscale packages contain a variety of RNA molecules, especially non-coding RNAs such as microRNAs and long non-coding RNAs. These EV-RNAs function as important messengers of cell-to-cell communication, shuttling between intestinal epithelial cells, immune cells, and even intestinal bacteria to modulate the intestinal microenvironment. Our study integrates the latest global research to uncover how these molecules function in IBD and how they can be used to improve patient treatment. ”
Professor Xiyang Wei, corresponding author of the study
The research team’s summary indicates that EV-RNA is involved in multiple core pathological processes in IBD. Pathogenic EV-RNA can trigger an exaggerated inflammatory response, damage the intestinal epithelial barrier (often referred to as “leaky gut”), and disrupt the balance of the gut microbiota, thereby exacerbating disease progression. On the contrary, beneficial EV-RNAs can reduce inflammation, repair damaged intestinal tissue, and restore mucosal homeostasis, presenting powerful therapeutic potential.
Of note, this review also highlights the systemic role of gut-derived EV-RNA in inducing extraintestinal complications of IBD. Outside the gastrointestinal tract, IBD is often associated with liver damage and cardiac dysfunction, significantly increasing patient morbidity. The researchers found that EV-RNA secreted from inflamed intestinal tissue can enter the bloodstream, reach distant organs, and directly control inflammatory responses in the liver and heart. This reveals important molecular mechanisms underlying these systemic complications.
One of the most promising clinical applications of EV-RNA highlighted in this study is its use as a non-invasive diagnostic biomarker. Unlike traditional invasive endoscopy, EV-RNA is stably protected from degradation by vesicles and can be reliably detected even in easily accessible body fluids such as plasma and saliva. This review cites multiple clinical studies showing that specific EV-RNA signatures, such as elevated long non-coding RNA H19 levels in plasma EVs, can distinguish between active IBD and disease remission with extremely high accuracy, with area under the curve (AUC) values ranging from 0.95 to 0.97. Salivary EV-derived microRNA panels have also shown good diagnostic performance, providing a truly non-invasive and patient-friendly tool for early screening and real-time monitoring of disease activity.
Regarding treatment, this review outlines various EV-RNA-based therapeutic strategies that have shown significant efficacy in preclinical IBD models. For example, mesenchymal stem cell-derived EVs (MSC-EVs) harbor various immunomodulatory miRNAs that can suppress excessive inflammation, promote intestinal barrier repair, and alleviate colitis in animal models. Compared to whole-cell stem cell therapy, these cell-free EVs have a much lower risk of immune rejection and tumor formation, making them safer therapeutic candidates.
More importantly, the research team points to the potential of dietary and plant-based EVs as oral therapeutic platforms. EVs extracted from natural sources such as bovine colostrum Ouren, Gotukola And tea contains functional miRNAs that can withstand the harsh acidic environment of the gastrointestinal tract and directly target inflamed intestinal tissue to exert anti-inflammatory effects. for example, Ouren Delivering specific miRNAs that restore zinc homeostasis in immune cells, thereby inhibiting neutrophil-induced intestinal tissue damage. On the other hand, bovine colostrum EVs harbor miRNAs that block the core NF-κB inflammatory signaling pathway. These natural plant-derived EVs provide a patient-friendly oral treatment option with minimal systemic side effects, opening new avenues for adjuvant therapy of IBD.
The review also states that engineered EVs represent another cutting-edge direction. Researchers can now modify EVs to display targeting molecules on their surface and load them with specific therapeutic RNAs, allowing for precise and personalized delivery to inflamed intestinal tissue. In preclinical models, these genetically engineered EVs have shown synergistic therapeutic effects, capable of not only suppressing pathogenic T cell activation but also delivering regulatory RNA to correct disease-causing molecular defects, providing new hope for patients with refractory IBD who are refractory to conventional treatments.
The research team also recognizes important challenges that need to be overcome to translate these promising findings into clinical practice. A major obstacle is the lack of standardized protocols for EV isolation, purification, and RNA detection, which leads to discrepancies in research results between different laboratories. Additionally, large-scale multicenter clinical trials are needed to verify the diagnostic and therapeutic efficacy of EV-RNA in human patients, as well as clear regulatory pathways for EV-based therapeutics.
“For millions of IBD patients, this field is rapidly evolving and EV-RNA is at the forefront of this progress,” Professor Wei added. “Our review integrates all the latest evidence and shows that these molecules are not passive bystanders of the disease, but core regulators that can be targets for both diagnosis and treatment. We hope that this work will guide future research and accelerate the translation of these discoveries from the laboratory to the clinic, ultimately leading to more effective and personalized treatments for IBD patients worldwide.”
Although further research and standardization is required, this comprehensive review represents an important step forward in understanding the role of EV-RNA in IBD and opens new possibilities to transform the diagnosis, monitoring, and treatment of this chronic gastrointestinal disorder.
sauce:
Reference magazines:
Len, R. Others. (2026) From biomarkers to therapeutics: extracellular vesicular RNA plays a key role in inflammatory bowel disease management. ExRNA. DOI: 10.55092/exrna20260003. https://www.elspub.com/doi/10.55092/exrna20260003
